INTRODUCTION
============

Exposure to heliox, in lieu of nitrogen-containing breathing gas, has been shown to have neuro-protective \[[@R1]-[@R3]\] and cardio-protective \[[@R4]-[@R7]\] effects in the setting of ischemia/ reperfusion. Suggested mechanisms for these beneficial effects include activation of mitochondrial Ca++ sensitive potassium channels \[[@R8]\], protective kinase-signaling cascades \[[@R7]\] and mild uncoupling leading to decreased ROS (reactive oxygen species) production \[[@R4]\]. It has also been suggested that substituting helium for nitrogen in breathing gas might limit reperfusion injury by a mechanical modus; i.e. reducing nitrogen bubble formation within the cell. Reperfusion injury is a consequence of restoring blood flow to tissue after a period of ischemia. During ischemia, nitrogen is present in the cell in larger amounts than oxygen. Damaged mitochon-drial membranes allow nitrogen uptake causing swelling in the mitochondria, making the mitochondria unable to take up oxygen when it is restored, limiting recovery of oxidative metabolism and leading to irreversible injury \[[@R9]\].

A reduction in necrosis occurring with ischemia is the primary objective for interventions applied to patients after acute myocardial infarction. However, another key objective is reducing reperfusion injury. The no-reflow phenomenon is an important component of reperfusion injury following infarction and reperfusion and is characterized by an anatomic area of hypo-perfusion or no perfusion related to microvascular obstruction. No-reflow occurs after opening the occluded major epicardial coronary artery. In patients, it is seen using angiography, intracoronary contrast echocar-diography or magnetic resonance imaging. Experimentally, it is delineated by vascular tracers such as thioflavin S and carbon black. Early after the reperfusion of an epicardial coronary artery, zones demonstrating a perfusion defect are small; however over time there is a progressive increase in no-reflow in areas that initially were perfused. In patients, large zones of no-reflow are associated with adverse outcome \[[@R10]-[@R12]\].

Previous studies in rabbits \[[@R7],[@R13]-[@R17]\] have tested the effects of heliox on necrosis when administered as a preconditioning mimetic and observed a reduction in infarct size. However, a preconditioning intervention has limited clinical application, so the purpose of this study was to test the effects of continuous heliox breathing, starting before the onset of ischemia and continuing throughout reperfusion, on the development of necrosis and no-reflow defect after myocardial ischemia and reperfusion in the rabbit model.

METHODS
=======

The animals used in these studies were maintained in accordance with the policies and guidelines of the Position of the American Heart Association on research animal use (American Heart Association, 1985) and the Guide for Care and Use of Laboratory Animals (2010). The protocol was approved by The Institutional Animal Care and Use Committee of Good Samaritan Hospital.

Surgical and Experimental Procedures
------------------------------------

The techniques used for the rabbit model of acute myocardial infarction have been described previously \[[@R18]\]. In brief, anesthetized, open-chest male New Zealand White rabbits (2.5 to 3.3 kg) received 30 minutes of coronary artery occlusion (CAO) followed by 3 hours of reperfusion. Body temperature was maintained using a heating pad. Arterial blood pressure and heart rate were recorded throughout the procedure. The anatomic no-reflow zone was measured using thioflavin S staining, a fluorescent yellow dye that stains endothelium and serves as a marker of regional perfusion. The no-reflow zone appears as a non-fluorescent, dark area, and regions of perfusion appear brightly fluorescent under ultraviolet light. Blue pigment injected through a catheter in the left atrial appendage with the coronary artery re-occluded demarcated the ischemic risk zone, and necrosis was measured using *in vitro* staining with triphenyltetrazolium chloride. Measurements of risk zone, no-reflow zone and infarct size were calculated as previously described \[[@R18]\].

Treatment Groups
----------------

During surgical preparation, all rabbits were intubated and respired with room air supplemented with 0.1 L/min of 100% oxygen. The respirator was set to an initial volume of 7 ml/kg/inspiration and a rate of 55-60 breathes per minute. The volume per inspiration was adjusted to maintain pO^2^ of \~100 mm Hg, and the rate was adjusted to maintain pCO^2^ values between 35-45 mm Hg. After surgical preparation was completed, the rabbits were randomly assigned to treatment group. If the rabbit was assigned to the control group, no changes to respiration were made. If the rabbit was assigned to the heliox group, the gas mixture was changed to heliox (30% oxygen and 70% helium) for the duration of the study (15 min stabilization, 30 min coronary artery occlusion, and 3 hrs reperfusion). Prospective exclusion criteria were 1) death occurring before the study was completed, or 2) an ischemic risk zone of \<10% of the left ventricle.

Statistical Analyses
--------------------

Data were calculated and tabulated using Excel work sheets. All data summary and statistical analyses were performed using SAS (Version 9.3, Cary, NC). Left ventricular weight, infarct size, area at risk, and area of no-reflow were compared using Student's t test. Changes in hemodynamic and arterial blood gas variables over time were analyzed by repeated measures analysis of variance. Analysis of covariance was used to test for a group effect on the regression models of necrotic myocardium with risk zone and no-reflow zone with risk zone and necrosis. Data are expressed as mean ± SEM.

RESULTS
=======

Experimental Animals
--------------------

Nineteen rabbits were assigned to the study. One control rabbit died of ventricular fibrillation at 8 minutes after coronary artery occlusion. Two hearts (one control and one heliox) were excluded on the basis of the prospective exclusion criterion of an ischemic risk zone \<10% of the left ventricle. Data here are reported on the remaining 8 rabbits in each group. Rectal temperatures on average remained within 0.2° C of baseline (39.0 °C) in both groups (data not shown).

Arterial Blood Gas Levels
-------------------------

Arterial blood gas levels were measured throughout the protocol and used to maintain blood gas levels within physiologic range. There were no differences between groups in pH, pCO^2^, pO2 or oxygen saturation between groups or over the time period of the study (data not shown).

Heart Rate and Blood Pressure
-----------------------------

Both groups were similar with respect to baseline values of heart rate and mean arterial blood pressure (Fig. **[1](#F1){ref-type="fig"}**). Heart rates remained stable throughout the duration of the study, but arterial pressures decreased over time after coronary artery occlusion as is normally seen in this model. There were no significant differences between groups. Thus breathing helium instead of nitrogen had a neutral effect on hemodynamics.

Extent of the Ischemic Risk Zone, Necrosis and No-reflow
--------------------------------------------------------

The average size of the risk zones, expressed as a percentage of the left ventricle (LV), was similar in both groups and comprised 29 ± 2% of the left ventricle in the control group and 28 ± 2% in the heliox group (Table **[1](#T1){ref-type="table"}**). Therefore, on average, both groups had an equal size ischemic insult during coronary artery occlusion. Breathing a helium mix instead of a gas containing nitrogen failed to reduce myocardial necrosis. Infarct size, expressed as a percent of the risk region was 49 ± 5% in controls and 44 ± 4% in the heliox group (p = ns; Fig. **[2](#F2){ref-type="fig"}**). In addition, the extent of no-reflow was not reduced by heliox treatment, as the no-reflow zone expressed both as a percentage of the risk zone and percentage of the necrotic zone was similar in both groups (Table **[1](#T1){ref-type="table"}** and Fig. **[3](#F3){ref-type="fig"}**).

DISCUSSION
==========

Helium and Cardioprotection
---------------------------

An early study suggested that breathing a helium mixture versus air alone during acute myocardial infarction might be protective. In the late 1960s, Pifarre and coworkers, in one of the first studies examining the potential positive effects of breathing helium, showed that when dogs in the acute phase of circumflex coronary artery occlusion breathed a gas mixture containing 50 percent air, 30 percent oxygen and 20 percent helium, ventricular fibrillation was completely prevented. In another group breathing 20% oxygen and 80 % helium, VF occurred in 8 %; in the control group breathing air, VF occurred in more than half of the animals \[[@R19]\].

It was not until recently that the effects of heliox breathing were tested on the development of myocardial necrosis. In 2007, Pagel and coworkers^13^ tested heliox breathing administered as a preconditioning agent. Rabbits were respired with heliox in 3 5-minute cycles interspersed with 5 minutes nitrogen-oxygen mix before index ischemia and reperfusion (30 minutes, followed by three hours of reperfusion). Heliox was not given during the prolonged-ischemia or reperfusion periods \[[@R13]\]. The authors found that this procedure reduced myocardial infarct size to a degree similar to that of ischemic preconditioning. Data showed that this protection was associated with an activation of pro-survival kinases and inhibition of opening of the mitochondrial permeability transition pore \[[@R13]\]. It has since been shown that in both rabbits \[[@R7],[@R13],[@R15]\] and young (but not old) rats \[[@R20]\], infarct size is reduced by this treatment. In addition, heliox has been shown to be effective in a model of "late preconditioning" \[[@R21]\].

One small clinical study of forearm ischemia tested heliox administered starting 15 minutes before ischemia (15 minutes) and continuing into the reperfusion period. Heliox breathing reduced markers of inflammation, but failed to improve the hyperemic response (author's endpoint for nitric oxide bioavailability and endothelial function) \[[@R22]\].

Results From Our Study
----------------------

Although heliox breathing appears to be of benefit when used as a preconditioning agent, preconditioning has limited clinical application for the treatment of acute myocardial infarction. The onset of infarction is unpredictable, and a preconditioning therapy needs to be instituted prior to the onset of myocardial ischemia. Therefore, we chose to test the effect of heliox when administered not in a preconditioning fashion, but throughout ischemia and reperfusion. We tested continuous heliox breathing on infarct size and the extent of no-reflow in our rabbit model. Data from the study indicates that when helium replaces nitrogen in breathing gas during the entire period of ischemia/reperfusion, the heart is not protected from injury. Infarct size and the extent of the no-reflow zone were of similar size in both groups. Breathing heliox had a neutral effect on heart rate and blood pressure.

Results from our study are similar to those of an investigation by Fukuda and coworkers \[[@R23]\] who tested the effects of heliox breathing in an acute mouse model of hepatic ischemia/reperfusion. Heliox was started during the ischemic period and continued throughout reperfusion. After 90 minutes of ischemia and 3 hours of reperfusion, cell death, enzyme release and levels of hepatic malondialdehyde were similar in control and heliox breathing animals.

Regarding the effect of heliox on the infarct size there would appear to be a slight, but not statistical, trend for a reduction, and the extremes (20% on one heliox and 75% on one control) would tend to support that possibility. A most favorable effect from heliox would be to reduce reperfusion injury following interventions such as TPA, anti-platelet therapy, angioplasty, stent or even by-pass operations. This raises the speculation that heliox might have shown more diverging benefit if the rabbits received other treatment, e.g. anti-platelet agents, at the time of ligature release.

Study Limitations
-----------------

We did not test heliox breathing as a preconditioning agent to reduce infarct size, nor did we assess the effects of this intervention on myocardial function. Thus we cannot address if heliox would have had a beneficial effect in our model had these been tested. Also, we cannot rule out the possibility that heliox might be beneficial in other cardiac or non-cardiac models of ischemia/reperfusion.

Summary
-------

Continuous heliox breathing does not appear to be protective in the setting of acute myocardial infarction in the rabbit model. Heliox respiration (30% oxygen + 70% helium) given during 30 minutes of ischemia and 180 minutes of reperfusion did not alter infarct size or the extent of no-reflow. Heliox did not change heart rate or blood pressure or arterial blood gas variables.
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![Heart rate (beats per minute) and mean arterial pressure (mm Hg) in the two groups measured over the study. Heart rates remained stable throughout the duration of the study, but arterial pressures decreased over time after coronary artery occlusion as is normally seen in this model. There were no significant differences between groups.](TOCMJ-8-1_F1){#F1}

![The average size of the risk zones, expressed as a percentage of the left ventricle (left) was similar in both groups. Therefore, on average, both groups had an equal size ischemic insult during coronary artery occlusion. There was no significant difference between groups in infarct size, expressed as a percentage of the risk zone (right).](TOCMJ-8-1_F2){#F2}

![The no-reflow zone expressed both as a percentage of the risk zone (left) and percentage of the necrotic zone (right) was similar in both groups.](TOCMJ-8-1_F3){#F3}

###### 

Body weight, Risk Region, Infarct Size and No-Reflow in the two treatment groups.

  Parameter                        Control       Heliox        P value
  -------------------------------- ------------- ------------- ---------
  Body Weight (Kg)                 2.82 ± 0.1    2.80 ± 0.12   0.93
  Left Ventricle (LV) Weight (g)   4.09 ± 0.25   3.83 ± 0.22   0.45
  Risk Region (%LV)                29 ± 2        28 ± 2        0.68
  Infarct Size (% risk region)     49 ± 5        44 ± 4        0.41
  No-reflow (% risk region)        29 ± 4        28 ± 3        0.79
  No-reflow (% necrotic region)    59 ± 8        65 ± 5        0.47
